Lekarze w Xinjiang Province, Chiny — Strona 2

Jiang Dongmei is a Senior Consultant at Sir Run Run Shaw Hospital focused on cardiovascular disease diagnosis and treatment, including hypertension, coronary heart disease, arrhythmia, and heart failure. She also leads prevention and rehabilitation management of heart disease, especially after interventional surgery. She graduated from Zhejiang University School of Medicine in 2012 with an M.D.

Hu Huihui is a deputy chief physician in Pulmonary and Critical Care Medicine at Sir Run Run Shaw Hospital. She specializes in diagnosing and treating lung cancer and diagnosing lung nodules, using bronchoscopy technology with an emphasis on pulmonary interventional therapy. After earning her medical degree from Zhejiang University School of Medicine, she completed post-doctoral fellowships at SRRSH.

He Feifang is a neurologist and pain-management specialist at Sir Run Run Shaw Hospital, directing the Spinal Cerebrospinal Fluid Leak Program / Center for Intracranial Hypotension Management. He also chairs the Stop Spinal CSF Leak Association China. His clinical focus includes spontaneous intracranial hypotension and spinal CSF leaks, migraine and cervicogenic/tension headaches, neuropathic pain (PHN, DPPN), and cancer pain.

Gu Zichun is a Consultant at Sir Run Run Shaw Hospital specializing in eye plastic surgery and aesthetic procedures. He performs blepharoplasty, fat aspiration and autologous fat injection, body and contour shaping, and nose plastic surgery, with additional work in micro injection, scar treatment, and surface tumor resection and repair. He trained at Zhejiang University School of Medicine (graduated and master’s in 2002) and received a second prize award from the China Association of Plastic Surgery and Cosmetic Surgery.

Fan Shunwu is a professor at Sir Run Run Shaw Hospital with more than 40 years of medical experience. His work is linked to bone metastasis-related diagnosis and treatment, addressing challenges such as late detection on X-ray and CT. SRRSH article content describes a proposed early-stage tumor-cell killing strategy by targeting tumasteoclasts.